National and Kapodistrian University of Athens
Σχεδιασμός και ανάπτυξη νέων θεραπευτικών μέσων έναντι μορίων ανοσιακής διαφυγής του χρυσίζοντα σταφυλόκοκκου (Staphylococcus aureus) για την αντιμετώπιση λοιμώξεων
Abstract
dc:descriptionStaphylococcus aureus is a human pathogen that has an increasingly negative impact on human health. S. aureus can cause a broad range of potential inflammatory complications such as sepsis, endocarditis and toxic-shock syndrome. Its emerging antibiotic resistance and formidable immune evasion arsenal have emphasized the need for more effective approaches - such as the generation of monoclonal Abs- to neutralize virulence-promoting factors released by this pathogen. Complement is a crucial innate immune sentinel that protects from bacterial infection. S. aureus has been shown to produce proteins presenting complement inhibitory activity, such as Efb (Extracellular Fibrinogen Protein) and Eap (extracellular adherence protein). This study aimed at the development and evaluation of human recombinant antibodies that target key immune evasion mechanisms of S. aureus through Efb and Eap. Furthermore, our study addressed crucial structure-function interactions of Eap isoforms that dictate the virulence of various S. aureus strains.Initially we isolated donor-derived anti-EfbC IgGs that attenuate S. aureus survival through enhanced neutrophil killing. A phage library screen against EfbC yielded a panel of mini-Abs that displayed high selectivity for their target. All 12 mini-Abs were analyzed for their binding affinity and kinetics through an SPR-based approach. We also observed that specific mini-Abs (A1-A4) inhibit the binding of EfbC to C3 and its activated fragments C3b and C3d by disrupting contacts essential for complex formation. The inhibitory mini-Abs efficiently reversed the growth-promoting effect of Efb on S. aureus and decreased pathogen survival in a whole blood model of bacteremia. This neutralizing effect was associated with enhanced neutrophil-mediated killing of S. aureus, increased C5a production and modulation of IL-6 secretion. Finally, mini-Abs A1 and A2 afforded protection from S. aureus induced bacteremia in a murine renal abscess model, attenuating bacterial inflammation in kidneys.Gene silencing of another staphylococcal complement evasion molecule, Eap, decreased significantly the survival of S. aureus in a whole blood model of bacteremia, indicating that Eap is a valid target for the development of effective S. aureus-directed therapeutics. A human scFv library was therefore screened against the target protein Eap34 (Mu50) and the panning resulted in an scFv clone that selectively binds Eap (B1). SPR revealed binding of B1 to Eap-domain 4, however B1 did not inhibit Eap binding to C4b. Strikingly, addition of Eap and its complement modulatory fragment Eap34 enhanced S. aureus survival in a whole blood model of bacteremia while B1 significantly reversed this Eap-depended growth of S. aureus.To further delineate the effect of B1 blockade on various Eap isoforms, the two isoforms of Eap (Eap-Newman, Eap-Mu50) were produced and compared in terms of their S. aureus-growth promoting effect in whole blood. Eap-Mu50 increased significantly S. aureus survival in whole blood as compared to Eap-Newman. In addition, the Newman strain–encoded recombinant proteins Eap and Eap345 displayed higher binding affinity to fibrinogen compared to their Mu50-encoded counterparts. Moreover, Eap-Newman reduced neutrophil killing to a greater extent than Eap-Mu50, in agreement with its stronger complement C4b inhibitory activity over Eap-Mu50.Based on these findings, it is reasonable to hypothesize that reciprocal interactions between Eap and both the complement and coagulation systems determine the overall bacterial growth-promoting effect of Eap in whole blood. In this context, the stronger interaction of Eap-Newman with fibrinogen might mask its inhibitory effect on complement in a bacteremia setting.In conclusion, these studies have identified two mini-Abs A1 and A2 that present neutralizing activity against complement inhibitory protein Efb. The next step includes clinical evaluation of these Ab-based antimicrobial agents as leads for passive vaccination against staphylococcal infections. Moreover, this thesis provides the first evidence –at a molecular level- for a correlation between different isoforms of immune evasion proteins (Eap) and infectivity of different S. aureus strains. The long-term goal of this research is the development of a multivalent anti-serum composed of mAbs for passive vaccination against Staphylococcus aureus.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Georgoutsou-Spyridonos, Maria
- Γεωργούτσου-Σπυρίδωνος, Μαρία
Subjects
dc:subject × 16Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42280